Ms. Jenna McNeil reports

APPILI PRESIDENT AND CEO, DON CILLA TO JOIN ADITXT CEO, AMRO ALBANNA FOR ADITXT WEEKLY UPDATE ON APRIL 4, 2025

Appili Therapeutics Inc.'s president and chief executive officer, Dr. Don Cilla, PharmD, MBA, will join Aditxt Inc. co-founder and CEO Amro Albanna for the Aditxt weekly update on April 4, 2025. The discussion will cover the company's recent operational highlights, including $117-million in new federal funding applications and the status of the going-private transaction with Aditxt.

Dr. Cilla will join Aditxt to explore the escalating threat of emerging infectious diseases and highlight the vital role of strategic partnerships in developing innovative treatments and improving global public health. The Aditxt weekly update will also provide insights into Appili's diverse near-to-market portfolio, designed to address critical unmet patient needs.

Additionally, the discussion will highlight Appili's proven record in securing non-dilutive financing, showcasing $33.2-million in prior government awards and the recent submission of $117-million in new federal funding applications. By leveraging financial support, Appili can strengthen its ability to accelerate the development of new and existing infectious disease treatments aligned with public health priorities.

Participants are encouraged to register on-line in advance. The event will also include a Q&A (question-and-answer) session, with questions welcomed at info@appilitherapeutics.com.

Appili will join additional Aditxt weekly updates throughout the year.

About Appili Therapeutics Inc.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio driven and people focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The company is currently advancing a diverse range of anti-infectives, including a U.S. Food and Drug Administration-approved (FDA) ready-made suspension of metronidazole for the treatment of anti-microbial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical anti-parasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicentre of the global fight against infection.

We seek Safe Harbor.